China Current Deferred Revenue vs Long Term Debt Analysis

SXTC Stock

USD 0.38 0 0.53%

China SXT financial indicator trend analysis is way more than just evaluating China SXT Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether China SXT Pharmaceuticals is a good investment. Please check the relationship between China SXT Current Deferred Revenue and its Long Term Debt accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in China SXT Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

Current Deferred Revenue vs Long Term Debt

Current Deferred Revenue vs Long Term Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of China SXT Pharmaceuticals Current Deferred Revenue account and Long Term Debt. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between China SXT's Current Deferred Revenue and Long Term Debt is -0.59. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Long Term Debt in the same time period over historical financial statements of China SXT Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of China SXT's Current Deferred Revenue and Long Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of China SXT Pharmaceuticals are associated (or correlated) with its Long Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Long Term Debt has no effect on the direction of Current Deferred Revenue i.e., China SXT's Current Deferred Revenue and Long Term Debt go up and down completely randomly.

Correlation Coefficient

-0.59

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Long Term Debt

Long-term debt is a debt that China SXT Pharmaceuticals has held for over one year. Long-term debt appears on China SXT Pharmaceuticals balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on China SXT Pharmaceuticals balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.

Most indicators from China SXT's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into China SXT Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in China SXT Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

At present, China SXT's Enterprise Value Multiple is projected to increase slightly based on the last few years of reporting.

	2022	2023	2024	2025 (projected)
Gross Profit	426.3K	554.0K	498.6K	473.6K
Total Revenue	2.0M	1.9M	1.7M	1.6M

Gross Profit Total Revenue

China SXT fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Net Receivables	Capital Surpluse	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Property Plant Equipment	Short Long Term Debt Total	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Non Current Assets Total	Non Currrent Assets Other
Total Assets		0.87	0.94	0.97	0.92	-0.77	-0.78	0.97	0.97	0.34	0.91	-0.79	0.47	0.87	0.95	0.98	0.5	-0.34	0.4	0.84	0.53	0.57	-0.84	-0.93	0.94	0.89
Other Current Liab	0.87		0.93	0.78	0.71	-0.51	-0.56	0.78	0.78	0.35	0.66	-0.54	0.8	0.63	0.93	0.84	0.13	-0.14	0.1	0.58	0.15	0.55	-0.61	-0.86	0.83	0.78
Total Current Liabilities	0.94	0.93		0.84	0.78	-0.66	-0.6	0.85	0.85	0.43	0.77	-0.63	0.67	0.75	1.0	0.94	0.47	-0.25	0.2	0.69	0.48	0.57	-0.66	-0.83	0.86	0.81
Total Stockholder Equity	0.97	0.78	0.84		0.96	-0.79	-0.85	0.98	0.98	0.26	0.94	-0.85	0.31	0.9	0.85	0.94	0.48	-0.38	0.5	0.89	0.52	0.53	-0.91	-0.93	0.93	0.88
Net Tangible Assets	0.92	0.71	0.78	0.96		-0.87	-0.86	0.94	0.94	0.12	0.97	-0.86	0.17	0.97	0.79	0.88	0.48	-0.46	0.68	0.85	0.53	0.37	-0.89	-0.91	0.91	0.86
Retained Earnings	-0.77	-0.51	-0.66	-0.79	-0.87		0.71	-0.82	-0.82	0.18	-0.78	0.72	-0.05	-0.96	-0.68	-0.67	-0.54	0.79	-0.79	-0.6	-0.59	0.0	0.64	0.74	-0.86	-0.88
Accounts Payable	-0.78	-0.56	-0.6	-0.85	-0.86	0.71		-0.81	-0.81	-0.2	-0.82	0.96	-0.04	-0.81	-0.61	-0.73	-0.41	0.38	-0.56	-0.76	-0.46	-0.35	0.78	0.77	-0.76	-0.72
Cash	0.97	0.78	0.85	0.98	0.94	-0.82	-0.81		1.0	0.18	0.92	-0.83	0.31	0.9	0.87	0.93	0.5	-0.43	0.47	0.83	0.54	0.49	-0.88	-0.95	0.94	0.89
Cash And Short Term Investments	0.97	0.78	0.85	0.98	0.94	-0.82	-0.81	1.0		0.18	0.92	-0.83	0.31	0.9	0.87	0.93	0.5	-0.43	0.47	0.83	0.54	0.49	-0.88	-0.95	0.94	0.89
Net Receivables	0.34	0.35	0.43	0.26	0.12	0.18	-0.2	0.18	0.18		0.27	-0.27	0.4	-0.02	0.41	0.49	0.41	0.54	-0.4	0.46	0.37	0.81	-0.25	-0.09	0.06	-0.05
Capital Surpluse	0.91	0.66	0.77	0.94	0.97	-0.78	-0.82	0.92	0.92	0.27		-0.84	0.14	0.91	0.78	0.92	0.59	-0.34	0.6	0.89	0.63	0.48	-0.9	-0.85	0.81	0.74
Inventory	-0.79	-0.54	-0.63	-0.85	-0.86	0.72	0.96	-0.83	-0.83	-0.27	-0.84		0.02	-0.82	-0.64	-0.78	-0.55	0.32	-0.52	-0.83	-0.59	-0.46	0.81	0.76	-0.75	-0.69
Other Current Assets	0.47	0.8	0.67	0.31	0.17	-0.05	-0.04	0.31	0.31	0.4	0.14	0.02		0.11	0.66	0.46	-0.17	0.11	-0.36	0.12	-0.18	0.41	-0.11	-0.42	0.45	0.42
Other Stockholder Equity	0.87	0.63	0.75	0.9	0.97	-0.96	-0.81	0.9	0.9	-0.02	0.91	-0.82	0.11		0.76	0.81	0.54	-0.63	0.77	0.75	0.59	0.2	-0.79	-0.84	0.9	0.88
Total Liab	0.95	0.93	1.0	0.85	0.79	-0.68	-0.61	0.87	0.87	0.41	0.78	-0.64	0.66	0.76		0.94	0.47	-0.27	0.22	0.7	0.49	0.57	-0.67	-0.84	0.87	0.82
Total Current Assets	0.98	0.84	0.94	0.94	0.88	-0.67	-0.73	0.93	0.93	0.49	0.92	-0.78	0.46	0.81	0.94		0.57	-0.19	0.3	0.87	0.59	0.68	-0.84	-0.87	0.84	0.76
Short Term Debt	0.5	0.13	0.47	0.48	0.48	-0.54	-0.41	0.5	0.5	0.41	0.59	-0.55	-0.17	0.54	0.47	0.57		-0.27	0.3	0.57	1.0	0.36	-0.44	-0.24	0.34	0.3
Intangible Assets	-0.34	-0.14	-0.25	-0.38	-0.46	0.79	0.38	-0.43	-0.43	0.54	-0.34	0.32	0.11	-0.63	-0.27	-0.19	-0.27		-0.71	-0.06	-0.32	0.52	0.12	0.35	-0.55	-0.66
Common Stock	0.4	0.1	0.2	0.5	0.68	-0.79	-0.56	0.47	0.47	-0.4	0.6	-0.52	-0.36	0.77	0.22	0.3	0.3	-0.71		0.42	0.36	-0.32	-0.46	-0.42	0.52	0.56
Property Plant Equipment	0.84	0.58	0.69	0.89	0.85	-0.6	-0.76	0.83	0.83	0.46	0.89	-0.83	0.12	0.75	0.7	0.87	0.57	-0.06	0.42		0.6	0.72	-0.94	-0.75	0.72	0.61
Short Long Term Debt Total	0.53	0.15	0.48	0.52	0.53	-0.59	-0.46	0.54	0.54	0.37	0.63	-0.59	-0.18	0.59	0.49	0.59	1.0	-0.32	0.36	0.6		0.34	-0.48	-0.29	0.38	0.35
Property Plant And Equipment Net	0.57	0.55	0.57	0.53	0.37	0.0	-0.35	0.49	0.49	0.81	0.48	-0.46	0.41	0.2	0.57	0.68	0.36	0.52	-0.32	0.72	0.34		-0.63	-0.46	0.33	0.19
Current Deferred Revenue	-0.84	-0.61	-0.66	-0.91	-0.89	0.64	0.78	-0.88	-0.88	-0.25	-0.9	0.81	-0.11	-0.79	-0.67	-0.84	-0.44	0.12	-0.46	-0.94	-0.48	-0.63		0.85	-0.76	-0.67
Net Debt	-0.93	-0.86	-0.83	-0.93	-0.91	0.74	0.77	-0.95	-0.95	-0.09	-0.85	0.76	-0.42	-0.84	-0.84	-0.87	-0.24	0.35	-0.42	-0.75	-0.29	-0.46	0.85		-0.93	-0.88
Non Current Assets Total	0.94	0.83	0.86	0.93	0.91	-0.86	-0.76	0.94	0.94	0.06	0.81	-0.75	0.45	0.9	0.87	0.84	0.34	-0.55	0.52	0.72	0.38	0.33	-0.76	-0.93		0.99
Non Currrent Assets Other	0.89	0.78	0.81	0.88	0.86	-0.88	-0.72	0.89	0.89	-0.05	0.74	-0.69	0.42	0.88	0.82	0.76	0.3	-0.66	0.56	0.61	0.35	0.19	-0.67	-0.88	0.99

Click cells to compare fundamentals

China SXT Account Relationship Matchups

China SXT fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	34.5M	33.5M	29.6M	23.1M	26.6M	21.9M
Other Current Liab	15.7M	12.3M	8.5M	4.0M	4.6M	6.5M
Total Current Liabilities	18.6M	17.1M	14.5M	8.9M	10.2M	11.1M
Total Stockholder Equity	16.0M	16.4M	14.7M	13.9M	16.0M	10.7M
Net Tangible Assets	11.0M	9.4M	15.9M	16.4M	18.8M	19.8M
Retained Earnings	(10.0M)	(15.7M)	(21.6M)	(24.7M)	(22.2M)	(21.1M)
Accounts Payable	1.5M	1.5M	1.4M	1.3M	1.2M	1.4M
Cash	13.3M	15.5M	17.4M	12.1M	13.9M	9.2M
Cash And Short Term Investments	13.3M	15.5M	17.4M	12.1M	13.9M	9.2M
Net Receivables	7.8M	4.9M	1.3M	1.3M	1.2M	1.2M
Inventory	859.7K	1.0M	531.3K	809.8K	728.8K	799.6K
Other Current Assets	1.3M	995.8K	230.6K	6.8K	7.9K	7.5K
Other Stockholder Equity	25.3M	31.0M	35.6M	35.3M	40.6M	42.6M
Total Liab	18.6M	17.1M	14.9M	9.2M	10.6M	11.2M
Total Current Assets	23.2M	22.5M	19.5M	14.2M	16.4M	16.1M
Short Term Debt	37.1K	2.0M	3.4M	2.4M	2.7M	1.9M
Intangible Assets	45.8K	38.8K	27.9K	19.1K	17.2K	34.3K
Common Stock	62.1K	162.5K	913.8K	4.4M	5.0M	5.3M
Property Plant Equipment	1.8M	1.9M	1.8M	1.6M	1.8M	1.5M
Short Long Term Debt Total	43.4K	2.0M	3.8M	2.6M	3.0M	2.2M
Property Plant And Equipment Net	1.8M	1.6M	1.3M	564.7K	508.2K	482.8K
Current Deferred Revenue	257.4K	77.4K	165.5K	187.7K	168.9K	192.3K
Net Debt	(13.3M)	(13.5M)	(13.6M)	(9.4M)	(8.5M)	(8.9M)
Non Current Assets Total	11.3M	11.1M	10.0M	8.9M	10.2M	6.5M
Non Currrent Assets Other	9.2M	9.5M	8.7M	8.3M	9.6M	5.0M
Common Stock Shares Outstanding	28.8K	41.6K	267.0K	867.4K	997.5K	1.0M
Liabilities And Stockholders Equity	34.5M	33.5M	29.6M	23.1M	26.6M	23.8M
Non Current Liabilities Total	6.3K	3.6M	365.8K	294.7K	338.9K	598.3K
Property Plant And Equipment Gross	1.8M	3.4M	3.2M	3.1M	3.6M	2.4M
Short Long Term Debt	37.1K	2.0M	3.3M	2.3M	2.6M	2.1M
Accumulated Other Comprehensive Income	527.8K	956.1K	(197.6K)	(1.0M)	(923.2K)	(877.1K)
Other Assets	13.5K	112.8K	9.5M	9.5M	10.9M	11.4M
Net Invested Capital	16.0M	18.5M	18.1M	16.3M	18.8M	15.7M
Net Working Capital	4.7M	5.3M	5.0M	5.3M	6.1M	6.1M
Capital Stock	62.1K	162.5K	913.8K	4.4M	5.0M	5.3M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

CSX	CSX Corporation
ETON	Eton Pharmaceuticals
ALLT	Allot Communications

When determining whether China SXT Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of China SXT's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of China Sxt Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on China Sxt Pharmaceuticals Stock:

How To Invest In China

Details

Is China Stock a good investment?

Details

What is China SXT's Net Worth?

Details

Largest Personal Care Products Companies

View

Largest Drug Manufacturers - Specialty & Generic Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in China SXT Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.

Is Personal Care Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of China SXT. If investors know China will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about China SXT listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.426

Earnings Share

(3.57)

Revenue Per Share

2.223

Quarterly Revenue Growth

0.295

Return On Assets

(0.05)

The market value of China SXT Pharmaceuticals is measured differently than its book value, which is the value of China that is recorded on the company's balance sheet. Investors also form their own opinion of China SXT's value that differs from its market value or its book value, called intrinsic value, which is China SXT's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because China SXT's market value can be influenced by many factors that don't directly affect China SXT's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between China SXT's value and its price as these two are different measures arrived at by different means. Investors typically determine if China SXT is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, China SXT's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

China Current Deferred Revenue vs Long Term Debt Analysis

Current Deferred Revenue vs Long Term Debt

Current Deferred Revenue vs Long Term Debt Correlation Analysis

Correlation Coefficient

Current Deferred Revenue

Long Term Debt

China SXT fundamental ratios Correlations

China SXT Account Relationship Matchups

High Positive Relationship

High Negative Relationship

China SXT fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Liab	+ 1.0	Total Current Liabilities
Cash And Short Term Investments	+ 1.0	Cash
Short Long Term Debt Total	+ 1.0	Short Term Debt
Non Currrent Assets Other	+ 0.99	Non Current Assets Total
Total Current Assets	+ 0.98	Total Assets
Cash	+ 0.98	Total Stockholder Equity

Other Stockholder Equity	- 0.96	Retained Earnings
Net Debt	- 0.95	Cash And Short Term Investments
Net Debt	- 0.95	Cash
Current Deferred Revenue	- 0.94	Property Plant Equipment
Non Current Assets Total	- 0.93	Net Debt
Net Debt	- 0.93	Total Stockholder Equity